JP2008523073A5 - - Google Patents

Download PDF

Info

Publication number
JP2008523073A5
JP2008523073A5 JP2007545584A JP2007545584A JP2008523073A5 JP 2008523073 A5 JP2008523073 A5 JP 2008523073A5 JP 2007545584 A JP2007545584 A JP 2007545584A JP 2007545584 A JP2007545584 A JP 2007545584A JP 2008523073 A5 JP2008523073 A5 JP 2008523073A5
Authority
JP
Japan
Prior art keywords
medicament
medicament according
cancer
her2
tumor sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007545584A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008523073A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/044247 external-priority patent/WO2006063042A2/en
Publication of JP2008523073A publication Critical patent/JP2008523073A/ja
Publication of JP2008523073A5 publication Critical patent/JP2008523073A5/ja
Pending legal-status Critical Current

Links

JP2007545584A 2004-12-07 2005-12-06 Ｈｅｒ阻害剤を用いた治療のための患者の選択 Pending JP2008523073A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63394104P 2004-12-07 2004-12-07
PCT/US2005/044247 WO2006063042A2 (en) 2004-12-07 2005-12-06 Selecting patients for therapy with a her inhibitor

Publications (2)

Publication Number Publication Date
JP2008523073A JP2008523073A (ja) 2008-07-03
JP2008523073A5 true JP2008523073A5 (enExample) 2009-01-29

Family

ID=36177671

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007545584A Pending JP2008523073A (ja) 2004-12-07 2005-12-06 Ｈｅｒ阻害剤を用いた治療のための患者の選択

Country Status (14)

Country Link
US (2) US20060121044A1 (enExample)
EP (1) EP1825001A2 (enExample)
JP (1) JP2008523073A (enExample)
KR (1) KR20070085855A (enExample)
CN (1) CN101115849A (enExample)
AR (1) AR051524A1 (enExample)
AU (1) AU2005314127A1 (enExample)
BR (1) BRPI0518086A (enExample)
CA (1) CA2587519A1 (enExample)
MX (1) MX2007006529A (enExample)
NO (1) NO20073487L (enExample)
RU (1) RU2007125644A (enExample)
WO (1) WO2006063042A2 (enExample)
ZA (1) ZA200704796B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
CN1447696A (zh) 2000-05-19 2003-10-08 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
HRP20141111T1 (hr) * 2004-07-22 2015-01-02 Genentech, Inc. Sastav her2-protutijela
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ZA200704796B (en) * 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
ES2710439T3 (es) * 2005-01-21 2019-04-25 Genentech Inc Dosificación fija de anticuerpos HER
KR101253576B1 (ko) * 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
ATE520979T1 (de) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
JP2007135581A (ja) * 2005-10-20 2007-06-07 Japan Science & Technology Agency 自己免疫性血小板減少性紫斑病（ｉｔｐ）患者の血液細胞特異的遺伝子群
MX2008015581A (es) * 2006-06-05 2008-12-17 Genentech Inc Prolongacion de la supervivencia de pacientes con cancer con niveles elevados de egf o tgf-alfa.
EP2518508A1 (en) * 2006-11-28 2012-10-31 U3 Pharma GmbH Activated HER3 as a marker for predicting therapeutic efficacy
US7825127B2 (en) * 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
EP2126127B1 (en) 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
EP2899541A1 (en) * 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA2690334C (en) * 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9283276B2 (en) 2007-08-14 2016-03-15 Ludwig Institute For Cancer Research Ltd. Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
WO2009026705A1 (en) * 2007-08-24 2009-03-05 The University Of Western Ontario Method of diagnosing and treating osteoarthritis
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CA2729796C (en) 2008-07-08 2017-07-04 George Mason Intellectual Properties, Inc. Phosphorylated c-erbb2 as a superior predictive theranostic marker for the diagnosis and treatment of cancer
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
WO2011084496A1 (en) * 2009-12-16 2011-07-14 Abbott Biotherapeutics Corp. Anti-her2 antibodies and their uses
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
NZ604007A (en) 2010-05-27 2015-03-27 Genmab As Monoclonal antibodies against her2 epitope
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
KR101862832B1 (ko) 2010-11-01 2018-05-30 심포젠 에이/에스 Ｐａｎ―ｈｅｒ 항체 조성물
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
AU2012318541B2 (en) * 2011-10-06 2018-04-12 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
PT4241849T (pt) 2011-10-14 2024-10-30 Hoffmann La Roche Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
DK2968495T3 (da) 2013-03-15 2019-10-14 Daniel J Capon Hybrid immunoglobulin indeholdende en ikke-peptid-bro
AR095863A1 (es) 2013-04-16 2015-11-18 Genentech Inc Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
SI3116486T1 (sl) 2014-03-14 2020-07-31 Biomolecular Holdings Llc Hibridni imunoglobulin, ki vsebuje nepeptidilno vezavo
CN106163558A (zh) 2014-04-25 2016-11-23 豪夫迈·罗氏有限公司 用曲妥珠单抗‑mcc‑dm1和帕妥珠单抗治疗早期乳腺癌的方法
EP3304072A4 (en) * 2015-05-29 2018-12-05 Expression Pathology, Inc. Quantifying her2 protein for optimal cancer therapy
SI3302551T1 (sl) 2015-05-30 2024-10-30 F. Hoffmann-La Roche Ag Metode zdravljenja predhodno nezdravljenega her2-pozitivnega metastatskega raka dojk
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
GB201611580D0 (en) * 2016-07-01 2016-08-17 Aslan Pharmaceuticals Pte Ltd Method
CN110505880A (zh) 2016-11-04 2019-11-26 基因泰克公司 Her2阳性乳腺癌的治疗
EP3562844A1 (en) 2016-12-28 2019-11-06 Genentech, Inc. Treatment of advanced her2 expressing cancer
MY189536A (en) 2017-01-17 2022-02-16 Hoffmann La Roche Subcutaneous her2 antibody formulations
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
EP4171748A1 (en) 2020-06-29 2023-05-03 Genentech, Inc. Pertuzumab plus trastuzumab fixed dose combination

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5824311A (en) * 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
IL138034A0 (en) * 1998-03-27 2001-10-31 Genentech Inc Apo-2 ligand-anti-her-2 antibody synergism
BRPI9910332B8 (pt) * 1998-05-06 2021-05-25 Genentech Inc método para purificação de um polipeptídio a partir de uma composição
US6573043B1 (en) * 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
WO2000069460A1 (en) * 1999-05-14 2000-11-23 Genentech, Inc. TREATMENT WITH ANTI-ErbB2 ANTIBODIES
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) * 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AT500848B1 (de) * 1999-06-25 2008-01-15 Genentech Inc Humanisierte anti-erbb2-antikörper
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
JP4579471B2 (ja) * 1999-06-25 2010-11-10 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる前立腺癌の処置
PL202369B1 (pl) * 1999-08-27 2009-06-30 Genentech Inc Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
CN1447696A (zh) * 2000-05-19 2003-10-08 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
US20030190689A1 (en) * 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
HUP0600340A3 (en) * 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
US20040013297A1 (en) * 2002-07-18 2004-01-22 Roger Lo Method for performing color gamut compression
CA2500255A1 (en) * 2002-10-01 2004-04-29 Epigenomics Ag Method and nucleic acids for the treatment of breast cell proliferative disorders
WO2004046386A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
WO2004048525A2 (en) * 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP3170906B1 (en) * 2003-06-24 2018-08-22 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
EP1737489B1 (en) * 2004-04-08 2012-01-11 David B Agus ErbB2 antagonists for tumor pain therapy
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
HRP20141111T1 (hr) * 2004-07-22 2015-01-02 Genentech, Inc. Sastav her2-protutijela
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ZA200704796B (en) * 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
ES2710439T3 (es) * 2005-01-21 2019-04-25 Genentech Inc Dosificación fija de anticuerpos HER
KR101253576B1 (ko) * 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
US20060204505A1 (en) * 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
MX2008015581A (es) * 2006-06-05 2008-12-17 Genentech Inc Prolongacion de la supervivencia de pacientes con cancer con niveles elevados de egf o tgf-alfa.
ES2392630T3 (es) * 2006-08-21 2012-12-12 F. Hoffmann-La Roche Ag Terapia antitumoral con anticuerpos anti-VEGF

Similar Documents

Publication Publication Date Title
Jeon et al. Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1-dependent ACTA2 induction
Wilken et al. Primary trastuzumab resistance: new tricks for an old drug
Nami et al. Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer
Karamouzis et al. Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors
RU2007125644A (ru) Отбор пациентов для терапии ингибитором her
Boku HER2-positive gastric cancer
Chen et al. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells
Asiedu et al. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells
Yeon et al. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer
Ithimakin et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab
Carrion-Salip et al. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands
Takikita et al. Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma
Bedard et al. Stemming resistance to HER-2 targeted therapy
Chiu et al. HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients
Menyhart et al. A comprehensive outline of trastuzumab resistance biomarkers in HER2 overexpressing breast cancer
Jacobi et al. ErbB family signalling: a paradigm for oncogene addiction and personalized oncology
Nadeem Abbas et al. Advances in targeting the epidermal growth factor receptor pathway by synthetic products and its regulation by epigenetic modulators as a therapy for glioblastoma
Meulendijks et al. Phase Ib study of lumretuzumab plus cetuximab or erlotinib in solid tumor patients and evaluation of HER3 and heregulin as potential biomarkers of clinical activity
Zardavas et al. Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015
Sanz-Moreno et al. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer
JP2017501137A5 (enExample)
Majumder HER3: toward the prognostic significance, therapeutic potential, current challenges, and future therapeutics in different types of cancer
Wang et al. The role of HER3 in gastric cancer
Hatch et al. Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)
Rendell et al. Targeting tyrosine kinases in ovarian cancer: small molecule inhibitor and monoclonal antibody, where are we now?